Abstract
Oncolytic viruses are biological agents which can easily be delivered at high doses directly to the bladder through a catheter (intravesical), with low risk of systemic uptake and toxicity. To date, a number of viruses have been delivered intravesically in patients and in murine models with bladder cancer and antitumour effects demonstrated. Here, we describe in vitro methods to evaluate Coxsackie virus, CVA21, as an oncolytic virus for the treatment of human bladder cancer by determining the susceptibility of bladder cancer cell lines expressing differing levels of ICAM-1 surface receptor to CVA21.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barocas DA, Globe DR, Colayco DC et al (2012) Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol 8:421709
Svatek RS, Hollenbeck BK, Holmäng S et al (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66(2):253–262
Fuge O, Vasdev N, Allchorne P et al (2015) Immunotherapy for bladder cancer. Res Rep Urol 7:65–79
Potts KG, Hitt MM, Moore RB (2012) Oncolytic viruses in the treatment of bladder cancer. Adv Urol 2012:404581
Goldufsky J, Sivendran S, Harcharik S et al (2013) Oncolytic virus therapy for cancer. Oncolytic Virother 2:31–46
Delwar Z, Zhang K, Rennie PS et al (2016) Oncolytic virotherapy for urological cancers. Nat Rev Urol 13(6):334–352
Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Choi A, O’Leary M, Fong Y et al (2016) From benchtop to bedside: a review of oncolytic virotherapy. Biomedicine 4(3):18
Bradley S, Jakes AD, Harrington K et al (2014) Applications of coxsackievirus A21 in oncology. Oncolytic Virother 3:47–55
**ao C, Bator-Kelly CM, Rieder E et al (2005) The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure (Lond Engl 1993) 13(7):1019–1033
Shafren DR, Dorahy DJ, Ingham RA et al (1997) Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 71(6):4736–4743
Annels NE, Mansfield D, Arif M et al (2019) Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 25(19):5818–5831
Pourianfar HR, Javadi A, Grollo L (2012) A colorimetric-based accurate method for the determination of enterovirus 71 titer. Indian J Virol 23(3):303–310
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Relph, K., Arif, M., Pandha, H., Annels, N., Simpson, G.R. (2023). Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21. In: Hoffmann, M.J., Gaisa, N.T., Nawroth, R., Ecke, T.H. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 2684. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3291-8_20
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3291-8_20
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3290-1
Online ISBN: 978-1-0716-3291-8
eBook Packages: Springer Protocols